For Healthcare Professionals Outside the US

KISQALI is indicated for the treatment of women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone‑releasing hormone (LHRH) agonist.

As demonstrated in MONALEESA-7.1

UPDATED PREMENOPAUSAL
OS DATA
View the results
Postmenopausal
OS Data
Discover more
EXPERT PERSPECTIVE

on updated OS data

See videos

aBC, advanced breast cancer; CDK, cyclin-dependent kinase; HER2–, human epidermal growth factor receptor 2–negative; HR+, hormone receptor–positive.

References: 1. Tripathy D, Im S-A, Colleoni M, et al. Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2–) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib. Presented at: San Antonio Breast Cancer Symposium; December 8-12, 2020; San Antonio, TX. Poster PD2-04.